Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation
- PMID: 21417819
- DOI: 10.1517/17425255.2011.565331
Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation
Erratum in
- Expert Opin Drug Metab Toxicol. 2011 Jun;7(6):783
Abstract
Introduction: Nevirapine (NVP), a non-nucleoside reverse transcriptase inhibitor, has been an important component of HIV infection treatment for many years. Currently, twice-a-day dosing is required for the successful application of NVP immediate release (IR), but there is potential for a more convenient once-a-day antiretroviral combination.
Areas covered: The purpose of this article is to review the recent data on once-daily NVP extended release (XR) looking at all the important pharmacologic, pharmacokinetic and clinical data on NVP IR/XR through a systematic MEDLINE database search as well as a review of abstracts presented at international HIV meetings on NVP XR studies up to December 2010. The article provides the reader with an overview of all the pharmacodynamic and pharmacokinetic aspects of NVP IR/XR, as well as its preclinical and clinical efficacy and its safety.
Expert opinion: NVP XR is as effective as NVP IR among HIV-infected patients with a similar safety profile. NVP XR requires careful monitoring during initiation, but its favorable lipid profile may be of clinical benefit in reducing the risk for coronary artery disease in HIV-infected patients who are receiving long-term antiretroviral therapy. Further research is needed to predict short-term toxicity.
Similar articles
-
Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).HIV Med. 2012 Apr;13(4):236-44. doi: 10.1111/j.1468-1293.2011.00969.x. Epub 2011 Dec 4. HIV Med. 2012. PMID: 22136068 Clinical Trial.
-
Nevirapine extended-release for the treatment of HIV-1 infection.Expert Rev Anti Infect Ther. 2012 Jan;10(1):21-30. doi: 10.1586/eri.11.145. Expert Rev Anti Infect Ther. 2012. PMID: 22149611
-
Guidelines for the use of extended-release nevirapine in HIV-infected patients.Expert Opin Pharmacother. 2011 Dec;12(17):2713-8. doi: 10.1517/14656566.2011.630391. Epub 2011 Oct 29. Expert Opin Pharmacother. 2011. PMID: 22035406 Review.
-
Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.Antivir Ther. 2011;16(5):759-69. doi: 10.3851/IMP1803. Antivir Ther. 2011. PMID: 21817198 Clinical Trial.
-
Once-daily nevirapine XR: a brief overview of the safety and efficacy of a new formulation.J Int Assoc Physicians AIDS Care (Chic). 2012 Nov-Dec;11(6):369-73. doi: 10.1177/1545109712456427. Epub 2012 Aug 27. J Int Assoc Physicians AIDS Care (Chic). 2012. PMID: 22930796 Review.
Cited by
-
Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs).Viruses. 2023 Sep 25;15(10):1992. doi: 10.3390/v15101992. Viruses. 2023. PMID: 37896769 Free PMC article. Review.
-
Nevirapine-based regimens in HIV-infected antiretroviral-naive patients: systematic review and meta-analysis of randomized controlled trials.PLoS One. 2013 Oct 7;8(10):e76587. doi: 10.1371/journal.pone.0076587. eCollection 2013. PLoS One. 2013. PMID: 24116123 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical